Story

Mizuho Highlights 7 Top Healthcare Stocks Ahead of Key 2026 Catalysts

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Mizuho Highlights 7 Top Healthcare Stocks Ahead of Key 2026 Catalysts
Text size
Background

Mizuho has released its updated "Top Picks List" for the U.S. healthcare sector, spotlighting seven companies its analysts believe represent the highest-conviction, catalyst-driven opportunities. The selections, based on bottom-up analysis, span the biotechnology, medical device, and healthcare services industries.

Catalyst-Driven Selections

The list represents investment ideas from Mizuho's U.S. analysts, with conviction levels assessed by comparing the firm's own ratings, price targets, and earnings estimates against Bloomberg consensus data. The selected companies are notable for upcoming clinical trial results, strong product pipelines, or favorable market dynamics.

Biotechnology in Focus

Mizuho's report placed a strong emphasis on biotechnology firms with near-term data readouts and significant market potential. The highlighted companies include:

Sample IUX Markets – In-articleAd
  • Eyepoint Pharmaceuticals (EYPT): Named a top pick for its ophthalmology therapy Duravyu, with pivotal Phase 3 study data expected in August 2026 and later in the year.
  • Vaxcyte (PCVX): The firm sees its pneumococcal vaccine candidate as potentially best-in-class, targeting an $8 billion market. Key non-inferiority trial data is anticipated in the fourth quarter of 2026.
  • Erasca (ERAS): Highlighted for its RAS inhibitor portfolio, which Mizuho estimates could support risk-adjusted worldwide sales of approximately $6 billion by 2036.
  • Arcutis Biotherapeutics (ARQT): Mizuho noted potential upside to the company's 2026 Zoryve sales guidance of $480 million to $495 million.

Devices and Services Outlook

Beyond biotech, Mizuho identified opportunities in medical devices and healthcare providers, citing strong operational performance and strategic positioning.

  • AxoGen (AXGN): Following a key license for its Avance Nerve Allograft, Mizuho believes the company's full-year top-line growth could approach 20%, ahead of the current Street forecast of 18%.
  • Encompass Health (EHC): The firm pointed to strong demand, evidenced by 78.7% occupancy rates in the first quarter of 2026, and a strategy to significantly increase bed capacity.
  • Solventum (SOLV): After a business divestiture, the company is positioned to pay down debt. A proprietary Mizuho survey also indicated strong expected growth in dental patient volume and consumables for 2026.

Read next

More on Stocks
Back to latest news

LATEST